TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03257267

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cemiplimab
Description: Intravenous (IV) administration every 3 weeks (Q3W)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Investigator Choice (IC) Chemotherapy
Description: IC chemotherapy options include:~1. Antifolate: Pemetrexed~2. Topoisomerase 1 inhibitor: Topotecan or Irinotecan~3. Nucleoside analogue: Gemcitabine~4. Vinca alkaloid: Vinorelbine~The only chemotherapy treatments allowed in the control arm are any of the 5 drugs that are listed as IC options above.
Study: NCT00635427

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VPRIV®
Description: Intravenous infusion, every other week (EOW)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VPRIV®
Description: Intravenous infusion, every other week (EOW)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VPRIV®
Description: Intravenous infusion, every other week (EOW)
Study: NCT03583567

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chlorpheniramine and ranitidine
Description: Patient will receive intravenous chlorpheniramine and ranitidine prior to protamine.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% Normal Saline
Description: Patient will receive normal saline as placebo.
Study: NCT03428529

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine Oral Product
Description: Neoadjuvant Capecitabine concomitant to external beam radiotherapy
Study: NCT03758508

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: High Flow Oxygen nasal cannula
Description: High Flow Oxygen nasal cannula

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: High Flow Oxygen nasal cannula
Description: High Flow Oxygen nasal cannula

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Noninvasive ventilation
Description: In this arm, participants receive noninvasive ventilation through an interface (such as full face mask or oro-nasal mask) alternated with continuous high flow oxygen though humidified nasal cannula
Study: NCT01955811

Intervention type: DRUG
Group type: OTHER
Intervention: Administration of platelet concentrate and taking blood samples
Description: Patient with the need of a platelet transfusion, will have 4 intervention points. 1. directly before the start of the transfusion a blood sample will be drawn. 2. Patient receives the platelet transfusion. 3. One hour after the end of transfusion a second blood sample will be drawn. 4. 24 h after the end of the platelet transfusion a further bloos sample will be collected. The first two samples will be (beside blood cell counts) spiked in-vitro with different amounts of Human fibrinogen and blood clotting tests will be performed. The same with the 3. blood sample, but without spiking steps.
Study: NCT03408899

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PC-1005 gel
Description: PC-1005 (0.002% MIV-150/0.3% zinc acetate in 3.0% carrageenan gel) in 4 mL, 16 mL, and 32 mL doses administered rectally.
Study: NCT01631942

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC172-2021
Description: Administered as subcutaneous (s.c., under the skin) injections every other day for two weeks.~Escalation to next dose level is based on a safety evaluation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC172-2021
Description: Administered as subcutaneous (s.c., under the skin) injections every other day for two weeks.~Escalation to next dose level is based on a safety evaluation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC172-2021
Description: Administered as subcutaneous (s.c., under the skin) injections every other day for two weeks.~Escalation to next dose level is based on a safety evaluation.
Study: NCT02156258

Intervention type: DEVICE
Intervention: FFDM Mammography
Description: Standard mammography image collection

Intervention type: DEVICE
Intervention: FFDM Mammography
Description: Standard mammography image collection

Intervention type: DEVICE
Intervention: FFDM Mammography
Description: Standard mammography image collection

Intervention type: DEVICE
Intervention: DBT Mammography
Description: Collection of breast images using DBT mammography

Intervention type: DEVICE
Intervention: DBT Mammography
Description: Collection of breast images using DBT mammography

Intervention type: DEVICE
Intervention: DBT Mammography
Description: Collection of breast images using DBT mammography
Study: NCT01240746

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Licensed 2010-2011 Trivalent Influenza Vaccine, No Preservative
Description: 0.25 mL (6 to 35 months) or 0.5 mL (3 to \<9 years), Intramuscular

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Investigational Trivalent Influenza Vaccine with alternate B strain, No Preservative
Description: 0.25 mL (6 to 35 months) or 0.5 mL (3 to \<9 years), Intramuscular

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Quadrivalent Influenza Vaccine, No Preservative
Description: 0.25 mL (6 to 35 months), or 0.5 mL(3 to \<9 years), Intramuscular
Study: NCT03636256

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NanoDoce (direct injection)
Description: Subjects will receive NanoDoce injected into the index tumor resection site on the bladder wall, immediately following transurethral resection of the bladder tumor (TURBT)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NanoDoce (direct injection)
Description: Subjects will receive NanoDoce injected into the index tumor resection site on the bladder wall, immediately following transurethral resection of the bladder tumor (TURBT)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NanoDoce (intravesical instillation) - Visit 2 Instillation
Description: All subjects will receive an initial intravesical instillation within 2 hours of direct injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NanoDoce (intravesical instillation) - Visit 2 Instillation
Description: All subjects will receive an initial intravesical instillation within 2 hours of direct injection.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Institutional Standard of Care
Description: Group 2 (MIBC) will receive institutional standard of care treatments after the Visit 2 intravesical instillation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NanoDoce (intravesical instillation) - Induction and Maintenance Instillations
Description: Group 1 (NMIBC) will receive intravesical instillations in an Induction Period and a Maintenance Period.
Study: NCT03428529

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5Fluorouracil
Description: Neoadjuvant bolus 5-Fluorouracil concomitante to external beam radiotherapy
Study: NCT06240923

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Maxillary molars distalization
Description: Maxillary molars distalization by using a nickel titanium open coil spring as an posterior displacement device.
Study: NCT02455193

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Diet
Study: NCT03173339

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endotracheal intubation using laryngoscope
Description: Endotracheal intubation was done using laryngoscope for general anesthesia.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endotracheal intubation using laryngoscope
Description: Endotracheal intubation was done using laryngoscope for general anesthesia.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High remifentanil
Description: Remifentanil was started as 0.25 mcg/kg/min. Remifentanil dose was adjusted to maintain blood pressure (20% of preoperative blood pressure) and bispectral index (40-60) by 0.05 mcg/kg/min.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Low remifentanil
Description: Remifentanil was administered as 0.1 mcg/kg/min.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: High sevoflurane
Description: Sevoflurane was started as 0.5 MAC. Sevoflurane dose was adjusted to maintain blood pressure (20% of preoperative blood pressure) and bispectral index (40-60) by 0.2 %.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low sevoflurane
Description: Sevoflurane was administered as 0.5 MAC.
Study: NCT00599001

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SD-101
Description: Single subcutaneous escalating dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study: NCT03299985

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diaphragmatic myofascial release
Description: Subjects in this arm will receive different myofascial release techniques aimed to normalize the myofascial tension of the diaphragmatic muscle

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham myofascial release
Description: Subjects in this arm will receive the same manual techniques of the diaphragmatic myofascial release group, but without the myofascial stimulus
Study: NCT03810443

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Hyperventilation test
Description: The elements of the research consist of the Nijmegen questionnaire response, two dyspnea questionnaires (Dyspnea 12, MDP), a quality of life questionnaire (SF36), a psychological disorder screening questionnaire (HAD) and a diagnostic test: the hyperventilation test.
Study: NCT00879190

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Unasyn
Description: Unasyn 3 grams intravenously every 6 hours, plus intravenous normal saline placebo dose every 8 hours until 24 hours post delivery.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ampicillin/gentamicin
Description: Gentamicin 1.5mg/kg intravenously every 8 hours plus ampicillin 2 grams intravenously every 6 hours until 24 hours post delivery.
Study: NCT02623192

Intervention type: OTHER
Intervention: Patients who have performed the ARDS pulmonary function test
Study: NCT03837847

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health Coaching Calls
Description: Participants in this group will receive 12 weekly health coaching calls

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Participants in this group will receive 6 educational guides
Study: NCT01323556

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioural Therapy (CBT)
Description: 12 sessions of CBT including psychoeducation, behavioral analyses, interoceptive exposure and in-vivo exposure with interoceptive exposure during in vivo exposure

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioural Therapy (CBT)
Description: 12 sessions of CBT including psychoeducation, behavioral analyses, interoceptive exposure and in-vivo exposure without additional fear augmenting strategies
Study: NCT01327794

Intervention type: GENETIC
Intervention: polymorphism analysis

Intervention type: OTHER
Intervention: immunologic technique

Intervention type: OTHER
Intervention: laboratory biomarker analysis

Intervention type: OTHER
Intervention: medical chart review
Study: NCT00726453

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Resolute Zotarolimus-Eluting Coronary Stent
Description: Implantation of a Resolute Zotarolimus-Eluting Coronary Stent
Study: NCT01118299

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AMPLATZER Cardiac Plug
Description: AMPLATZER Cardiac Plug is a percutaneous transcatheter device

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: AMPLATZER Cardiac Plug
Description: AMPLATZER Cardiac Plug is a percutaneous transcatheter device
Study: NCT01067391

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tadalafil
Description: 20 mg tablet, administered once per study protocol

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo tablet administered once per study protocol
Study: NCT00778050

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin 600mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amoxicillin 600mg
Study: NCT04740853

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sensory Integration Therapy+Special Education
Description: Sensory integration is a theory first put forward by Ayres in 1972. It is a neurological process that organizes sensory stimuli from our body and our environment for use in the daily life. When the sensory integrity organization of individuals is provided, it is possible to use their body effectively against the environment. Sensory integration therapy, which is defined as a physiologically based process by Ayres and Dunn, also provides changes in individuals' occupations.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Sensory Integration Therapy+Special Education
Description: Sensory integration is a theory first put forward by Ayres in 1972. It is a neurological process that organizes sensory stimuli from our body and our environment for use in the daily life. When the sensory integrity organization of individuals is provided, it is possible to use their body effectively against the environment. Sensory integration therapy, which is defined as a physiologically based process by Ayres and Dunn, also provides changes in individuals' occupations.
Study: NCT02178514

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Formula fed with BabyNes Nutrition System
Study: NCT01064544

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: light therapy with the device: EnergyLight
Description: 2 hr of light therapy during each hemodialysis session

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: light therapy with the device: EnergyLight
Description: 2 hr of light therapy during each hemodialysis session
Study: NCT03766035

Intervention type: DEVICE
Intervention: SpyGlass DS I - II
Description: The SpyScope™ DS Access and Delivery Catheter (SpyScope™ DS Catheter) is a sterile, single-use endoscope that enables access and delivery of accessories to targeted pancreaticobiliary anatomy and displays live video when connected to a Spy Glass DS Digital Controller.
Study: NCT00190268

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3,4-diaminopyridine
Description: 3,4-diaminopyridine
Study: NCT03248037

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Netarsudil
Description: netarsudil opthalmic solution 0.02%

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo eye drops
Study: NCT04384900

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Prone position ventilation
Description: Patients are placed in a prone position using specialized equipment.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Prone position ventilation
Description: Patients are placed in a prone position using specialized equipment.
Study: NCT02650817

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RAD1901
Description: RAD1901, a novel selective ER degrader (SERD)
Study: NCT03613298

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HIFU (Focal One®)
Description: Endometriosic lesion localization and HIFU treatment will be conducted with the Focal One® device. The treatment area will be defined using sonography, pelvic MRI and a transrectal sonography data. Once the pre-defined lesion will be located with Focal One device, succession of HIFU exposure will then be used to treat maximum lesion volume, excluding a security margin of 3 mm with the digestive mucosae.
Study: NCT02870491

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Free Distribution
Description: Caretakers of children under 5-years-old will have access to free ORS and zinc

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Free Distribution
Description: Caretakers of children under 5-years-old will have access to free ORS and zinc

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Preemptive Delivery
Description: Caretakers of children under 5-years-old will have ORS and zinc delivered to their home

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Preemptive Delivery
Description: Caretakers of children under 5-years-old will have ORS and zinc delivered to their home
Study: NCT02788487

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Tongue retaining device
Description: Tongue retaining device is used for 3 weeks

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tongue retaining device
Description: Tongue retaining device is used for 3 weeks

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CPAP
Description: CPAP is used for 3 weeks

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CPAP
Description: CPAP is used for 3 weeks
Study: NCT05496023

Intervention type: DEVICE
Intervention: Percutaneous coronary intervention
Description: 1. Pre-PCI angio-FFR was calculated and virtual pullback was generated~2. Automated algorithm to calculate delta angio-FFR per unit length and co-registered onto coronary angiogram was developed~3. PCI was performed using 2nd generation DES
Study: NCT03409744

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: evinacumab
Description: Intravenous (IV) administration
Study: NCT04850989

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pico Goblin VR headset
Description: We worked with Limbix to tailor content on a Pico Goblin VR headset by creating two exposure therapy themes (general social skills training/dinner party or job interview) based on CBT principles and literature. The Pico Goblin VR headset projected a 5.5-inch diagonal screen size (depth: 139.7 mm; height: 122mm; width: 68mm) with 2560 x 1440-pixel resolution, 3 degrees of freedom, 92° field of view, a refresh rate of 70Hz, and 54-71mm interpupillary distance (Kyoto, 2017). It was chosen because displays of the pre-recorded VRE videos could be smoothly operated wirelessly with a tablet that showed the selected scenes in real-time. Further, the headset could be conveniently switched on and off, and dovetailed the participant's head motion. These scenes were filmed with a 360° stereoscopic camera, each lasting between 1.5 to 10 min.
Study: NCT02460510

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mannitol

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 3% hypertonic saline
Study: NCT03470077

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV nalbuphine 0.1 mg/kg with induction of anesthesia.
Description: Group A: 40 patients will receive IV nalbuphine 0.1 mg/kg with induction of anesthesia.~.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV nalbuphine 0.1 mg/kg at the end of surgery.
Description: Group B: 40 patients will receive IV nalbuphine 0.1 mg/kg at the end of surgery just before discontinuation of anesthesia.
Study: NCT01482611

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-47910382
Description: Type = exact number, unit = mg, number = 10, 75, 300, form = suspension, route = oral use.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-47910382
Description: Type = exact number, unit = mg, number = 30, 150, 600, form = suspension, route = oral use.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-47910382
Description: Type = exact number, unit = mg, number = To be determined, form = suspension, route = oral use.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-47910382
Description: Type = exact number, unit = mg, number = To be determined, form = suspension, route = oral use.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Type = exact number, unit = mg, number = equivalent of 10, 75, 300, form = suspension, route = oral use.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Type = exact number, unit = mg, number = equivalent of 30, 150, 600, form = suspension, route = oral use

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Type = exact number, unit = mg, number = equivalent dose to be determined, form = suspension, route = oral use.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Type = exact number, unit = mg, number = equivalent dose to be determined, form = suspension, route = oral use
Study: NCT03248297

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin
Description: Azithromycin tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin and amoxicillin
Description: azithromycin and amoxicillin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablet
Study: NCT02399332

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Community pharmacist involvement
Description: Collaborative involvement of the community pharmacists in formulating and following complex care plans
Study: NCT03528421

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IM19
Description: CAR-T cells

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Two days before cell infusion, all patients will be treated with fludarabine for 3 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Two days before cell infusion, all patients will be treated with Cyclophosphamide for 3 days
Study: NCT04614506

Intervention type: DEVICE
Intervention: Transcranial Magnetic Stimulation (TMS)
Description: Transcranial magnetic stimulation (TMS) is a method for noninvasive electrical cortical stimulation, where small intracranial currents are generated by a powerful, fluctuating, extracranial magnetic field. TMS is unique in its capacity for experimental, diagnostic, and therapeutic utility. Single pulse (spTMS) and paired-pulse TMS (ppTMS) have been used extensively to study, measure, and modulate cortical excitability and plasticity.

Intervention type: DEVICE
Intervention: Electroencephalogram (EEG)
Description: These will be an ambulatory EEG recordings that span 24 hours and done without sedation. Recordings will be performed using electrode locations specified by the international 10-20 system for standard clinical practice.
Study: NCT02980016

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rifapentine + isoniazid
Description: Rifapentine + isoniazid Once weekly rifapentine (at a dose of 900 mg) plus isoniazid (at a dose of 900 mg), with adjustment for participants weighing ≤50 kg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rifapentine + isoniazid
Description: Rifapentine + isoniazid Once weekly rifapentine (at a dose of 900 mg) plus isoniazid (at a dose of 900 mg), with adjustment for participants weighing ≤50 kg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Isoniazid
Description: Daily self-administered isoniazid (at a dose of 300 mg/daily), with adjustment for participants weighing ≤24 kg
Study: NCT04078386

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients received the test group Placebo weekly administered subcutaneously for 24 times.